Nautilus BiotechnolgyNAUT
About: Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. It has built a prototype of a single-molecule instrument, Proteomic Analysis System.
Employees: 161
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
200% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 3
69% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 13
22% more capital invested
Capital invested by funds: $151M [Q2] → $183M (+$32.4M) [Q3]
8% more funds holding
Funds holding: 77 [Q2] → 83 (+6) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q2] → 3 (+0) [Q3]
0.16% less ownership
Funds ownership: 51.35% [Q2] → 51.18% (-0.16%) [Q3]
Research analyst outlook
We haven’t received any recent analyst ratings for NAUT.
Financial journalist opinion
Based on 3 articles about NAUT published over the past 30 days